Format

Send to

Choose Destination
Oncolytic Virother. 2015 Sep 10;4:133-40. doi: 10.2147/OV.S66091. eCollection 2015.

Oncolytic virotherapy for human malignant mesothelioma: recent advances.

Author information

1
INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
2
Nantes CHU Hospital, Department of Thoracic and Digestive Oncology, Institut Pasteur, Paris, CNRS UMR-3569, France.
3
Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, CNRS UMR-3569, France.

Abstract

Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their ability to induce antitumor immune responses. In this review, we summarize preclinical and clinical data regarding the targeting of malignant mesothelioma (MM) by oncolytic viruses. We also discuss the potential of other oncolytic viruses that have already shown antitumor effects against several malignancies in advanced clinical trials but are yet to be tested against MM cells. Finally, we review how the activation of the immune system and combinations with other types of anticancer treatments could support the development of oncolytic virotherapy for the treatment of MM.

KEYWORDS:

antitumor immune responses; cancer virotherapy; immunotherapy; malignant mesothelioma; oncolytic viruses

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center